Literature DB >> 24652288

Regulation of fibroblast growth factor-inducible 14 (Fn14) expression levels via ligand-independent lysosomal degradation.

Sujatha Gurunathan1, Jeffrey A Winkles, Sankar Ghosh, Matthew S Hayden.   

Abstract

Fibroblast growth factor-inducible 14 (Fn14) is a highly inducible cytokine receptor that engages multiple intracellular signaling pathways, including nuclear factor-κB (NF-κB) and mitogen-activated protein kinase (MAPK). Fn14 expression is regulated by several cytokines and growth factors, and Fn14 is transiently up-regulated after injury. In contrast, in states of chronic inflammatory disease and in some solid tumors, Fn14 is persistently up-regulated. However, the post-translational regulation of Fn14 expression has not been directly investigated. Thus, we examined Fn14 proteostasis in the presence and absence of the Fn14 ligand TNF-like weak inducer of apoptosis (TWEAK). Similar to other TNF receptor superfamily members, we found that TWEAK induces Fn14 internalization and degradation. Surprisingly, we also observed rapid, TWEAK-independent, constitutive Fn14 internalization and turnover. Fn14 levels are maintained in cell culture by ongoing synthesis and trafficking of the receptor, leading to subsequent down-regulation by lysosomal degradation. Unexpectedly, the extracellular domain of Fn14 is necessary and sufficient for constitutive turnover. Based on these findings, we propose a model in which constitutive down-regulation of Fn14 facilitates dynamic regulation of Fn14 protein levels and prevents spontaneous or inappropriate receptor signaling.

Entities:  

Keywords:  Fn14; Inflammation; Proteostasis; Receptor Endocytosis; Receptor Regulation; Trafficking; Tumor Necrosis Factor (TNF); Tweak

Mesh:

Substances:

Year:  2014        PMID: 24652288      PMCID: PMC4036313          DOI: 10.1074/jbc.M114.563478

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  63 in total

1.  Brefeldin A causes disassembly of the Golgi complex and accumulation of secretory proteins in the endoplasmic reticulum.

Authors:  T Fujiwara; K Oda; S Yokota; A Takatsuki; Y Ikehara
Journal:  J Biol Chem       Date:  1988-12-05       Impact factor: 5.157

2.  Four different classes of inhibitors of receptor-mediated endocytosis decrease tumor necrosis factor-induced gene expression in human endothelial cells.

Authors:  J R Bradley; D R Johnson; J S Pober
Journal:  J Immunol       Date:  1993-06-15       Impact factor: 5.422

3.  TNF induces internalization of the p60 receptor and shedding of the p80 receptor.

Authors:  M Higuchi; B B Aggarwal
Journal:  J Immunol       Date:  1994-04-01       Impact factor: 5.422

4.  TWEAK can induce cell death via endogenous TNF and TNF receptor 1.

Authors:  P Schneider; R Schwenzer; E Haas; F Mühlenbeck; G Schubert; P Scheurich; J Tschopp; H Wajant
Journal:  Eur J Immunol       Date:  1999-06       Impact factor: 5.532

5.  The mitogen-inducible Fn14 gene encodes a type I transmembrane protein that modulates fibroblast adhesion and migration.

Authors:  R L Meighan-Mantha; D K Hsu; Y Guo; S A Brown; S L Feng; K A Peifley; G F Alberts; N G Copeland; D J Gilbert; N A Jenkins; C M Richards; J A Winkles
Journal:  J Biol Chem       Date:  1999-11-12       Impact factor: 5.157

6.  Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity.

Authors:  L Meng; R Mohan; B H Kwok; M Elofsson; N Sin; C M Crews
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-31       Impact factor: 11.205

7.  CD40 molecules induce down-modulation and endocytosis of T cell surface T cell-B cell activating molecule/CD40-L. Potential role in regulating helper effector function.

Authors:  M J Yellin; K Sippel; G Inghirami; L R Covey; J J Lee; J Sinning; E A Clark; L Chess; S Lederman
Journal:  J Immunol       Date:  1994-01-15       Impact factor: 5.422

8.  Antitumor activity of a humanized, bivalent immunotoxin targeting fn14-positive solid tumors.

Authors:  Hong Zhou; Walter N Hittelman; Hideo Yagita; Lawrence H Cheung; Stuart S Martin; Jeffrey A Winkles; Michael G Rosenblum
Journal:  Cancer Res       Date:  2013-05-30       Impact factor: 12.701

9.  Bafilomycin A1, a specific inhibitor of vacuolar-type H(+)-ATPase, inhibits acidification and protein degradation in lysosomes of cultured cells.

Authors:  T Yoshimori; A Yamamoto; Y Moriyama; M Futai; Y Tashiro
Journal:  J Biol Chem       Date:  1991-09-15       Impact factor: 5.157

Review 10.  Brefeldin A: insights into the control of membrane traffic and organelle structure.

Authors:  R D Klausner; J G Donaldson; J Lippincott-Schwartz
Journal:  J Cell Biol       Date:  1992-03       Impact factor: 10.539

View more
  12 in total

Review 1.  Tumor-targeted nanotherapeutics: overcoming treatment barriers for glioblastoma.

Authors:  Aniket S Wadajkar; Jimena G Dancy; David S Hersh; Pavlos Anastasiadis; Nhan L Tran; Graeme F Woodworth; Jeffrey A Winkles; Anthony J Kim
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2016-11-04

2.  Minimizing the non-specific binding of nanoparticles to the brain enables active targeting of Fn14-positive glioblastoma cells.

Authors:  Craig S Schneider; Jimena G Perez; Emily Cheng; Clark Zhang; Panagiotis Mastorakos; Justin Hanes; Jeffrey A Winkles; Graeme F Woodworth; Anthony J Kim
Journal:  Biomaterials       Date:  2014-12-13       Impact factor: 12.479

Review 3.  The TWEAK receptor Fn14 is a potential cell surface portal for targeted delivery of glioblastoma therapeutics.

Authors:  J G Perez; N L Tran; M G Rosenblum; C S Schneider; N P Connolly; A J Kim; G F Woodworth; J A Winkles
Journal:  Oncogene       Date:  2015-08-24       Impact factor: 9.867

4.  Decreased non-specific adhesivity, receptor targeted (DART) nanoparticles exhibit improved dispersion, cellular uptake, and tumor retention in invasive gliomas.

Authors:  Aniket S Wadajkar; Jimena G Dancy; Nathan B Roberts; Nina P Connolly; Dudley K Strickland; Jeffrey A Winkles; Graeme F Woodworth; Anthony J Kim
Journal:  J Control Release       Date:  2017-09-05       Impact factor: 9.776

5.  Endogenous TWEAK is critical for regulating the function of mouse uterine natural killer cells in an immunological model of pregnancy loss.

Authors:  Xuefeng Qi; Mingzhu Lei; Lijuan Qin; Mengjie Xie; Dandan Zhao; Jingyu Wang
Journal:  Immunology       Date:  2016-03-02       Impact factor: 7.397

6.  The Effect of MSCs Derived from the Human Umbilical Cord Transduced by Fibroblast Growth Factor-20 on Parkinson's Disease.

Authors:  Li Jinfeng; Wang Yunliang; Liu Xinshan; Wang Shanshan; Xu Chunyang; Xue Peng; Yang Xiaopeng; Xu Zhixiu; Yin Honglei; Cao Xia; Duan Haifeng; Cao Bingzhen
Journal:  Stem Cells Int       Date:  2016-05-05       Impact factor: 5.443

7.  Interaction of TWEAK with Fn14 leads to the progression of fibrotic liver disease by directly modulating hepatic stellate cell proliferation.

Authors:  Annika Wilhelm; Emma L Shepherd; Aldo Amatucci; Mamoona Munir; Gary Reynolds; Elizabeth Humphreys; Yazid Resheq; David H Adams; Stefan Hübscher; Linda C Burkly; Christopher J Weston; Simon C Afford
Journal:  J Pathol       Date:  2016-03-29       Impact factor: 7.996

8.  Lipopolysaccharide Upregulated Intestinal Epithelial Cell Expression of Fn14 and Activation of Fn14 Signaling Amplify Intestinal TLR4-Mediated Inflammation.

Authors:  Xuefeng Qi; Lijuan Qin; Ruijing Du; Yungang Chen; Mingzhu Lei; Meiyu Deng; Jingyu Wang
Journal:  Front Cell Infect Microbiol       Date:  2017-07-11       Impact factor: 5.293

9.  Autophagy differentially regulates TNF receptor Fn14 by distinct mammalian Atg8 proteins.

Authors:  Hila Winer; Milana Fraiberg; Adi Abada; Tali Dadosh; Bat-Chen Tamim-Yecheskel; Zvulun Elazar
Journal:  Nat Commun       Date:  2018-09-14       Impact factor: 14.919

10.  Decreased nonspecific adhesivity, receptor-targeted therapeutic nanoparticles for primary and metastatic breast cancer.

Authors:  Jimena G Dancy; Aniket S Wadajkar; Nina P Connolly; Rebeca Galisteo; Heather M Ames; Sen Peng; Nhan L Tran; Olga G Goloubeva; Graeme F Woodworth; Jeffrey A Winkles; Anthony J Kim
Journal:  Sci Adv       Date:  2020-01-15       Impact factor: 14.136

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.